Exelixis Inc. EXEL
$52.65
▼ -0.69% 24H
About
Exelixis Inc. is an oncology-focused biotechnology company dedicated to the discovery, development, and commercialization of new medicines for difficult-to-treat cancers. Its lead product, CABOMETYX tablets (cabozantinib), treats advanced renal cell carcinoma in patients following prior anti-angiogenic therapy and supp…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees1,077
TickerEXEL
Statistics
Market Cap$13.36B
Revenue (TTM)$2.32B
Net Income$782.6M
Net Margin33.7%
EPS$2.78
P/E17.72
P/S5.66
P/B7.01
EV/EBITDA12.79
ROE41.0%
Dividend Yield—
Price$52.65
Data: Twelve Data · Revenue = mcap / P/S